Candel Therapeutics (CADL) EBT: 2020-2023
Historic EBT for Candel Therapeutics (CADL) over the last 4 years, with Dec 2023 value amounting to -$5.4 million.
- Candel Therapeutics' EBT rose 31.61% to -$5.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$33.7 million, marking a year-over-year increase of 3.54%. This contributed to the annual value of -$30.2 million for FY2024, which is 10.44% up from last year.
- As of Q4 2023, Candel Therapeutics' EBT stood at -$5.4 million, which was up 40.34% from -$9.0 million recorded in Q3 2023.
- Candel Therapeutics' 5-year EBT high stood at -$2.4 million for Q2 2020, and its period low was -$9.8 million during Q2 2023.
- Moreover, its 3-year median value for EBT was -$8.5 million (2021), whereas its average is -$7.9 million.
- Per our database at Business Quant, Candel Therapeutics' EBT tumbled by 197.01% in 2021 and then spiked by 31.61% in 2023.
- Candel Therapeutics' EBT (Quarterly) stood at -$6.1 million in 2020, then dropped by 27.57% to -$7.8 million in 2021, then decreased by 1.60% to -$7.9 million in 2022, then surged by 31.61% to -$5.4 million in 2023.
- Its last three reported values are -$5.4 million in Q4 2023, -$9.0 million for Q3 2023, and -$9.8 million during Q2 2023.